Cargando…

Prescription Drug Promotion from 2001-2014: Data from the U.S. Food and Drug Administration

The volume of prescription drug promotion over time is often measured by assessing changes in ad spending. However, this method obscures the fact that some types of advertising are more expensive than others. Another way to measure the changes in prescription drug promotion over time is to assess th...

Descripción completa

Detalles Bibliográficos
Autores principales:	Sullivan, Helen W., Aikin, Kathryn J., Chung-Davies, Eunice, Wade, Michael
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Public Library of Science 2016
Materias:	Research Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4858269/ https://www.ncbi.nlm.nih.gov/pubmed/27149513 http://dx.doi.org/10.1371/journal.pone.0155035

Ejemplares similares

Direct-to-Consumer Promotion of Prescription Drugs on Mobile Devices: Content Analysis
por: Aikin, Kathryn J, et al.
Publicado: (2017)

The U.S. Food and Drug Administration: Drug Information Resource for Formulary Recommendations
por: Marchand, Heidi C., et al.
Publicado: (2012)

The Significance of Information Posted on the U.S. Food and Drug Administration’s Website
por: Cook, G. Elliott, et al.
Publicado: (2013)

Vaccines, pharmaceutical products, and bioterrorism: challenges for the U.S. Food and Drug Administration.
por: Zoon, K C
Publicado: (1999)

Why the Watchdog Won’t Bite: U.S. Food and Drug Administration Challenges
por: Lex, Joe
Publicado: (2016)

Impact of the U.S. Food and Drug Administration Cardiovascular Assessment Requirements on the Development of Novel Antidiabetes Drugs
por: Hirshberg, Boaz, et al.
Publicado: (2011)

The United States Food and Drug Administration and Prescription Drug Promotion
por: Kalola, Ankur S., et al.
Publicado: (2019)

U.S. Food and Drug Administration: Review for the Emergency Physician of Approval Process and Limitations
por: Zuabi, Nadia, et al.
Publicado: (2016)

A Proposed Framework for Patient-Focused Policy at the U.S. Food and Drug Administration
por: Kuehn, Carrie M.
Publicado: (2019)

Association of Advisory Committee Votes With US Food and Drug Administration Decision-Making on Prescription Drugs, 2010-2021
por: Daval, C. Joseph Ross, et al.
Publicado: (2023)

Testimonials and Informational Videos on Branded Prescription Drug Websites: Experimental Study to Assess Influence on Consumer Knowledge and Perceptions
por: Sullivan, Helen W, et al.
Publicado: (2018)

Pediatric dosing for locally acting drugs in submissions to the U.S. Food and Drug Administration between 2002 and 2020
por: Abulwerdi, Gelareh A., et al.
Publicado: (2023)

Trends in hospital admissions due to antidepressant-related adverse drug events from 2001 to 2011 in the U.S.
por: Parihar, Harish S., et al.
Publicado: (2017)

Promotion of Prescription Drugs to Consumers and Providers, 2001–2010
por: Kornfield, Rachel, et al.
Publicado: (2013)

Trends in Canadian prescription drug purchasing: 2001–2020
por: Hofmeister, Mark, et al.
Publicado: (2022)

Relative Food Prices and Obesity in U.S. Metropolitan Areas: 1976-2001
por: Xu, Xin, et al.
Publicado: (2014)

Priority-based assessment of food additives database of the U.S. Food and Drug Administration Center for Food Safety and Applied Nutrition.
por: Benz, R D, et al.
Publicado: (1991)

A Mixture of U.S. Food and Drug Administration–Approved Monoaminergic Drugs Protects the Retina From Light Damage in Diverse Models of Night Blindness
por: Leinonen, Henri, et al.
Publicado: (2019)

Prescriptions for Codeine or Hydrocodone Cough and Cold Medications to US Children and Adolescents Following US Food and Drug Administration Safety Communications
por: Chua, Kao-Ping, et al.
Publicado: (2021)

U.S. Food and Drug Administration-Certified Food Dyes as Organocatalysts in the Visible Light-Promoted Chlorination of Aromatics and Heteroaromatics
por: Rogers, David A., et al.
Publicado: (2020)

Descriptive Analysis of Good Clinical Practice Inspection Findings from U.S. Food and Drug Administration and European Medicines Agency
por: Sellers, Jenn W., et al.
Publicado: (2022)

Cyberpharmacies and the role of the US Food And Drug Administration
por: Henney, Jane E
Publicado: (2001)

The US Food and Drug Administration’s Intersection with Dermatology
por: Luke, Markham C.
Publicado: (2022)

ArrayTrack--supporting toxicogenomic research at the U.S. Food and Drug Administration National Center for Toxicological Research.
por: Tong, Weida, et al.
Publicado: (2003)

U.S. Food and Drug Administration perspective of the inclusion of effects of low-level exposures in safety and risk assessment.
por: Gaylor, D W, et al.
Publicado: (1998)

The U.S. Food and Drug Administration Risk Assessment on Lead in Women’s and Children’s Vitamins Is Based on Outdated Assumptions
por: Miodovnik, Amir, et al.
Publicado: (2009)

Association Between US Drug Price and Measures of Efficacy for Oncology Drugs Approved by the US Food and Drug Administration From 2015 to 2020
por: Miljković, Miloš D., et al.
Publicado: (2022)

Correction to: Descriptive Analysis of Good Clinical Practice Inspection Findings from U.S. Food and Drug Administration and European Medicines Agency
por: Sellers, Jenn W., et al.
Publicado: (2022)

Characteristics of Recent Generic Drug Approvals by the US Food and Drug Administration
por: Jiao, Kuo, et al.
Publicado: (2019)

Use of Extrapolation in New Drug Approvals by the US Food and Drug Administration
por: Feldman, Daniel, et al.
Publicado: (2022)

Trends in Bone Morphogenetic Protein Usage since the U.S. Food and Drug Administration Advisory in 2008: What Happens to Physician Practices When the Food and Drug Administration Issues an Advisory?
por: Mckie, Janay, et al.
Publicado: (2013)

Prescription Drug Diversion: Predictors of Illicit Acquisition and Redistribution in Three U.S. Metropolitan Areas
por: Harris, Shana, et al.
Publicado: (2015)

Anticancer Drugs Approved by the US Food and Drug Administration From 2009 to 2020 According to Their Mechanism of Action
por: Olivier, Timothée, et al.
Publicado: (2021)

Publisher Correction: Descriptive Analysis of Good Clinical Practice Inspection Findings from U.S. Food and Drug Administration and European Medicines Agency
por: Sellers, Jenn W., et al.
Publicado: (2022)

Participation of the elderly, women, and minorities in pivotal trials supporting 2011–2013 U.S. Food and Drug Administration approvals
por: Downing, Nicholas S., et al.
Publicado: (2016)

Review of Evidence Supporting 2022 US Food and Drug Administration Drug Approvals
por: Kaplan, Robert M., et al.
Publicado: (2023)

Dietary Cholesterol Intake and Sources among U.S Adults: Results from National Health and Nutrition Examination Surveys (NHANES), 2001–2014
por: Xu, Zhe, et al.
Publicado: (2018)

Time From Authorization by the US Food and Drug Administration to Medicare Coverage for Novel Technologies
por: Sexton, Zachary A., et al.
Publicado: (2023)

Remdesivir for COVID-19 and acute kidney injury: disproportionality analysis of data from the U.S. Food and Drug Administration Adverse Event Reporting System
por: Li, Xiaotong, et al.
Publicado: (2023)

US food and drug administration Indian site inspections: An experience
por: Mahajan, Pooja, et al.
Publicado: (2012)

Cannot write session to /tmp/vufind_sessions/sess_69bech86p8q3jgm1ra8fn185fr